GlassScriptPhysician profile
Sandra A Criscuolo
NPI 1487052189
$10,755.63
in general payments reported to CMS, 2019-2025
50 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,608 · 2022: $2,181 · 2023: $2,361 · 2024: $2,329 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,772 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,771.64 |
| Education | $195.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,634.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,115.19 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,004.12 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $748.03 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $661.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $527.41 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.65 | 2021-2025 | Jardiance, Ofev |
| Regeneron Healthcare Solutions, INC. | $297.76 | 2021-2022 | |
| Exact Sciences Corporation | $277.47 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $233.96 | 2022-2025 | Vpriv, Trintellix, Glassia |
| Actelion Pharmaceuticals US, INC. | $214.67 | 2024-2025 | Opsumit, Uptravi |
| Madrigal Pharmaceuticals | $187.81 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.52 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $156.29 | 2024-2025 | Auvelity |
| Abbott Laboratories | $153.75 | 2025 | Freestyle Libre 3 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Criscuolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.